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 Summary  
 
The 2013-2016 Ebola virus disease (EVD) outbreak in West Africa was associated with 
unprecedented challenges in the provision of care to EVD patients, including lack of pre-
existing isolation and treatment facilities, patients' reluctance to present for medical care due 
to fear of a high risk of mortality in treatment units, lack of effective Ebola virus-specific 
therapy and limitations in provision of supportive medical care. Case fatality rates (CFR) in 
West Africa were initially greater than 70% but over time decreased with increasing clinical 
and health system experience that included improvements in supportive care. To inform 
optimal care in a future EVD outbreak, we employed the Grading of Recommendations 
Assessment, Development and Evaluation (GRADE) methodology to develop evidence-
informed guidelines for the delivery of supportive care to patients admitted to Ebola 
treatment units. 
1,2 
 
  
 Introduction 
 
The 2013-2016 Ebola Virus Disease (EVD) outbreak in West Africa was associated with 
unprecedented challenges in the provision of care to EVD patients, including need for acute 
care that outstripped health worker numbers, lack of pre-existing treatment and isolation 
facilities, a lack of Ebola virus (EBOV)-specific treatments and, possibly,  limitations in the  
provision of supportive medical care.  1,2  
 
The clinical manifestations of EVD include a febrile, multisystem illness, with a predominance 
of gastrointestinal symptoms and signs – nausea, vomiting, diarrhea and abdominal pain – 
that frequently lead to hypovolemia, metabolic acidosis, renal dysfunction, and multi-system 
organ dysfunction.1-5 
 
With initial severe mismatches in care demand and system capacity, and reluctance to 
present for treatment, the initial risk of mortality was greater than 70%. Individualized clinical 
supportive care improved as community health and Ebola treatment units (ETUs) developed.6  
This care included better symptom control, laboratory-facilitated diagnosis of organ 
dysfunction, treatment of shock with enteral and parenteral fluids and electrolytes, and rapid 
diagnosis or empiric treatment of concomitant illness such as malaria and bacterial infections.  
Associated with these measures, case fatality rate (CFR) dropped to approximately 40% across 
the region, and fell further with increasing clinical and health system experience and 
capacity.7  
 
These experiences suggested the need to develop an evidence-based approach to the 
supportive care of patients with EVD.  Therefore, we developed evidence-informed guidelines 
for the delivery of supportive care to patients admitted to Ebola treatment units during a 
future outbreak using the Grading of Recommendations Assessment, Development and 
Evaluation (GRADE) methodology.8  
 
Scope and definitions 
 
These guidelines focus on the delivery of supportive care measures to patients in ETUs where 
health care resources are limited, a context typical in EVD outbreaks. The guidelines may be 
relevant to other infectious diseases with clinical syndromes similar to Ebola managed in 
isolation facilities (e.g. other hemorrhagic fever). The target audiences include health 
workers, governmental and non-governmental health agencies, public health organizations, 
local and clinical facility managers, and health policymakers at all levels. 
 
Group composition and meeting  
 
The multidisciplinary guidelines panel comprised 34 participants: 10 critical care physicians (2 
specialized in pediatric care), 1 critical care nurse, 2 emergency medicine physicians, 2 general 
practice physicians, 5 infectious diseases physicians, 1 lawyer, 1 psychologist and bioethicist, 
4 public health experts, 3 health research methodologists, 1 qualitative researcher, 1 EVD 
survivor, and 3 World Health Organization staff observers (see Appendix).  
 
The panel met for two days in London, UK in August 2016 and voted on six recommendations. 
The panel finalized two additional recommendations during two follow-up teleconferences in 
October 2016. Voting panelists participated as individuals rather than as representatives of 
organizations of which they were members.   
 
Formulating questions 
 
The steering committee used data from a quantitative survey and structured interviews of 
health workers involved in the international response to the West African EVD outbreak to 
inform the questions addressed by these guidelines.  
 
Search strategy and selection criteria 
 
The complete systematic review appears in the appendix. Briefly, the search strategy for our 
systematic review of interventions for shock and shock-like syndromes in resource-limited 
settings included an extensive list of illnesses that share characteristics with EVD (shock, 
ebola, cholera, sepsis and other severe diarrheal illnesses) and was not limited to specific 
interventions. We searched the following databases from inception to February 2016: 
Medline, Medline In-Process, Embase, Cochrane Database of Systematic Reviews, Cochrane 
Central, African Index Medicus, PubMed (supplemental for non-Medline records). 
Additional data to populate the evidence summary was acquired by a more targeted search 
of pre-MEDLINE and grey literature (e.g. medical history textbooks).  
 
The evidence summary followed the GRADE framework,9 in which confidence in evidence is 
rated “very low,” “low,” “moderate” or “high”. Confidence based on randomized controlled 
trials begins as high; confidence from observational studies begins as low. Confidence can be 
rated down for risk of bias,10 imprecision,11 inconsistency,12 indirectness,13 and publication 
bias.14 Observational evidence can be rated up for a large magnitude of association, a dose-
response gradient or if all unaccounted confounders would increase confidence in estimates 
of effect.  
 
Formulating recommendations 
 
The panel voted on the direction and the strength (strong or conditional) of each 
recommendation. Voting on recommendations was by secret ballot. For a strong 
recommendation we required 80% of votes in favour and smaller proportion in favour of a 
strong recommendation would result in a conditional recommendation. In making 
recommendations, the panel considered the magnitude of benefits and harms15, the quality 
of supporting evidence, and underlying values and preferences. Following the GRADE 
framework,9 we report our overall confidence in estimates of effect (i.e. the quality of 
supporting evidence) using the ratings “very low,” “low,” “moderate” or “high”. The 
confidence in effect estimates from randomized controlled trials begins as high, while 
confidence in the evidence from observational studies begins as low. Confidence can be rated 
down for risk of bias,10 imprecision,11 inconsistency,12 indirectness,13 and likelihood of 
publication bias.14 Observational evidence can be rated up in the presence of a large 
magnitude of association, a dose-response gradient or if all unaccounted confounders 
increase confidence in estimates of effect. The steering committee suggested confidence 
ratings for each evidence summary; the final assessments were achieved by consensus among 
voting panel members.  
 
Table 1 presents interpretations of strong and conditional recommendations from the 
perspectives of patients, clinicians and policy-makers.8 We restricted strong 
recommendations when evidence was of low or very low quality to situations of very high 
mortality in which almost all informed individuals will choose a possibly effective intervention, 
even if evidentiary support is limited.15  
 
Values and preferences 
 
We specified the following value and preference judgments that informed the 
recommendations: we placed a very high value on uncertain, substantial mortality reduction 
associated with any of the interventions and a lower value on very uncertain increase in EBOV 
transmission to healthcare providers; we placed a much lower value on rare complications of 
antibiotic therapy than on uncertain mortality benefit associated with antibiotic 
administration; we placed a high value on uncertain improvement in psychological well-being 
of patients and a lower value on very low and uncertain risk of EBOV transmission to the 
family; we placed a very high value on the reduction of pain suffered by EVD patients and a 
lower value on potential negative perceptions associated with the use of specific medications, 
in particular opioids. 
 
Other considerations 
 
We discussed, but did not make recommendations regarding 1) resources, feasibility and 
equity, 2) recommendations for interventions considered routine in high-income countries, 
3) diagnosis and treatment of malaria, 4) distinct vulnerable populations, 5) the limitations of 
making inferences from data collected in high-resource settings, and 6) the importance of 
continuing clinical research during outbreaks of infectious diseases and, more generally, in 
low and middle-income countries. A description of the group consensus on these issues 
appears in the appendix. 
 
  
Recommendations 
 
The clinical questions, strength of each recommendation and confidence in the underlying 
evidence appear in Table 2. 
 
1. We recommend (strong) administering oral rehydration solution in an adequate amount 
over non-standardized rehydration (moderate confidence). 
 
Indirect evidence gathered from other febrile gastro-intestinal syndromes with relevance to 
Ebola - Cholera: Although the pathophysiology of EBOV and cholera infections differ, both 
often result in profuse diarrheoa leading to intravascular volume depletion, hypotension, 
organ hypoperfusion and, in severe cases, shock. The first case series of oral rehydration 
therapy for cholera reported a reduction in CFR of severe cases in a British prison from 
approximately 50% to 3%.16 In the most severe cases, mortality approached 100% without 
rehydration, but <9% died with oral rehydration therapy.16 In a before-after study among 
Bangladeshi refugees with cholera and cholera-like illness in India in 1971, the CFR fell from 
approximately 30% to 3.6% after introduction of oral rehydration therapy.17  
 
Human-to-human EBOV transmission: Ebola virus is transmitted through direct contact with 
blood or body fluids and possibly through direct skin contact of a person with symptomatic 
EVD; airborne transmission has never been conclusively reported.18 EBOV transmission risk is 
extremely low with proper infection prevention and control (IPC) practices including 
appropriate personal protective equipment (PPE).18-20 In 2007, 14 health workers were 
infected with EBOV in Uganda before an isolation ward with basic IPC was established, and 
none afterwards.21 An unrecognized case of EVD in South Africa had direct contact with over 
300 health workers; only one was infected with EBOV.18,22 Although over 800 health workers 
were infected with EBOV during the 2013-2016 West Africa outbreak, most transmissions 
occurred in situations without adequate IPC measures (e.g. early in the outbreak, at non-
Ebola treatment units where patients were not identified as having EVD, when IPC practices 
were infrequently or improperly applied, or in the community).18 Our recommendations apply 
to contexts in which health workers will use appropriate IPC practices and will have contact 
with patients for reasons other than encouraging oral intake.  Therefore the intervention will 
not constitute large incremental exposure.  
 
Conclusion: Oral rehydration therapy probably reduces mortality and is unlikely to increase 
transmission of EBOV to health workers.  
 
Remark: This recommendation focuses on ensuring actual fluid intake rather than simply the 
delivery of oral rehydration solution. Patients who are too young or sick to prepare and drink 
oral rehydration solution independently require active assistance from healthcare providers. 
Adequacy of oral fluid intake refers to the volume that will prevent or correct signs of 
hypovolemia and should be considered on an individual basis (see recommendation 3).  
 
2. We recommend (strong) parenteral administration of fluids over no parenteral 
administration for patients unable to drink or whose volume losses are larger than oral 
volume intake (moderate confidence). 
 
Low- versus high-income countries: Early in the 2013-2016 West African EVD outbreak, 
systematic administration of intravenous fluids was uncommon and 1230/1737 (70.8%) EVD 
patients died,19 compared with 5/27 (18.5%) EVD patients treated with intravenous fluid 
rehydration in the United States and Europe (relative risk [RR] 0.26, 95% confidence interval 
[CI]0.12 to 0.58; risk difference [RD]-52.4%, 95% CI -29.7% to -62.3%; P<0.0001).23 Given that 
care in high-income countries encompassed many other interventions, this provides indirect 
supportive evidence for parenteral fluids. 
 
Time-series from single outbreaks: The Hastings Police Training Centre clinic in Freetown, 
Sierra Leone reported a decreasing CFR over time from 47.7% (n=151) in the first month, to 
31.7% (n=126) in the second month, to 23.4% (n=304) in the third month24 (first versus last 
time period RR 0.49, 95% CI 0.38 to 0.64; risk difference -24.3%, 95% CI -17.3% to -29.7%; 
P<0.0001). Similarly, the CFR across West Africa was greater than 70% between January and 
March 2014, and decreased to less than 40% between July and September 2015.7 This 
coincided with increased efforts towards improved supportive care, including parenteral fluid 
therapy when necessary. During the 1995 Zaire (now Democratic Republic of Congo) Ebola 
outbreak, 231 of 292 (79.1%) died before intravenous fluids were available and 14 of 25 
(56.0%) after they were introduced (RR 0.71, 95% CI 0.50 to 1.00; RD -23.1%, 95% CI -39.7% 
to +0.6%; P=0.055).25 Improved access to parenteral therapy represents one potential 
explanation for lower CFRs in these analyses. 
 
Case series of hypovolemic shock: Intravenous fluid resuscitation was first studied clinically 
during World War II: the survival of many soldiers was attributed to the administration of 
colloids and blood transfusions.26 Intravenous crystalloid solution was introduced during the 
Vietnam War and associated to a reduction in CFR from hypovolemic shock.26 However, 
original reports of the military case series are not readily available. Based on these initial 
reports, intravenous fluid resuscitation became standard of care for hypovolemic shock.26 All 
140 patients with cholera and hypotension survived in a case series of patients treated with 
intravenous fluid in India in 1965.27 
 
Human-to-human EBOV transmission: See evidence summary accompanying 
recommendation 1. Additional use of open-bore needles used during venous cannulation to 
administer parenteral fluids potentially increases the risk of EBOV transmission . Although 
deep needlestick injuries are probably a high risk for EBOV transmission28, these remain 
infrequent events when precautions are taken, such as using needles with safety features.29  
 
Conclusion: Parenteral administration of fluids probably reduces mortality in patients who 
are unable to drink or who have inadequate oral intake to keep up with current volume losses.  
 
Remark: Options for parenteral fluid administration include peripheral and central 
intravenous30,31 or intraosseous routes.32 Enteral fluids via nasogastric tube may be an 
acceptable alternative for selected patients (e.g. children with difficult intravenous access 
with adequate gastrointestinal motility, mild-moderate volume depletion, and tolerance of a 
nasogastric tube) and with sufficient provider technical skill. A three-arm randomized clinical 
trial comparing albumin fluid boluses, saline solution boluses or no boluses in 3141 children 
less than 12 years old with severe febrile illness and impaired perfusion showed better 
survival among patients who were treated without fluid boluses.33 We did not consider data 
from this trial as relevant to patients with EVD because few patients in this trial suffered from 
dehydration (less than 10%), gastroenteritis-like syndromes were systematically excluded, 
and because patients in both study arms received maintenance intravenous fluids, which is 
encompassed in the current recommendation. While there was consensus on the superiority 
of parenteral fluid administration of fluids over no parenteral administration when patients 
are unable to drink or whose volume losses are larger than oral volume intake, we 
acknowledge the lack of reliable data to guide the titration or cessation of parenteral fluid 
administration. 
 
 
3. In all patients with EVD, we recommend (strong) systematically monitoring and charting 
of vital signs and volume status over no systematic monitoring or charting (low confidence).  
 
Hypovolemia in adults: A systematic review of hypovolemia in adults identified several 
diagnostically helpful clinical signs.34 A pulse increment of ≥30 beats/min or severe dizziness 
when standing from lying is highly sensitive (0.97, 95% CI 0.91 to 1.0) and specific (0.98, 95% 
CI 0.97 to 0.99) for severe hypovolemia, defined as acute blood volume loss >600mL. Supine 
tachycardia (pulse >100 beats/min; specificity 0.96, 95% CI 0.88 to 99) and supine 
hypotension (systolic blood pressure <95mmHg; specificity 0.97, 95% CI 0.90 to 1.0) are 
helpful to confirm hypovolemia. Stool output can be measured reliably and guide rehydration 
requirements: in a case series, all 41 patients with severe cholera survived who received 
intravenous rehydration in a 1:1 ratio with stool output volume.27 
 
Hypovolemia in children: A systematic review of hypovolemia in children identified helpful 
clinical signs.35 Prolonged capillary refill was the most reliable predictor of volume depletion 
(likelihood ratio positive test  4.1 [95% CI 1.7 to 9.8], likelihood ratio negative test 0.57 [95% 
CI 0.39 to 0.82]). A prospective cohort study found that the 12-point DHAKA score (see 
Appendix) combining mental status, respiration, skin pinch and the presence of tears may 
improve detection of hypovolemia.36  
 
Early warning scores in adults; Two cluster-randomised control trials have examined the 
effects of medical outreach and early warning systems. In the first, 23 hospitals were 
randomised; there was no significant effect (adjusted odds ratio [OR] for composite outcome 
of cardiac arrest, unexpected death, or unplanned ICU admission 0.98; 95% CI 0.83 to 1.16).37 
The second trial randomised 16 hospital wards and found that the intervention reduced 
hospital mortality (adjusted OR 0.52; 95% CI 0.32 to 0.85).38 A meta-analysis was not possible 
due to heterogeneity.39 A systematic review included 4 before-after studies of variable 
quality:40 3 of these studies suggested that using an early warning score improves outcomes.  
 
Early warning scores in children: The Paediatric Early Warning Score (PEWS) score identified 
children at risk of cardiac arrest (area under the receiver operating characteristics curve 0.87, 
95% CI 0.85 to 0.89) in a case-control study of 2074 individuals evaluated at 4 hospitals.41 
 
Human-to-human EBOV transmission: See evidence summary accompanying 
recommendation 1. 
 
Conclusion: Monitoring and documentation of vital signs to detect hypovolemia and early 
warning signs of poor outcomes might reduce mortality and is unlikely to increase 
transmission of EBOV to health workers.  
 
Remark: 'Vital signs' refer to components of the physical examination that can ascertain 
volume status (i.e. heart rate, blood pressure, gastro-intestinal fluid loss, urine output, and, 
in children, capillary refill, skin pinch and tears), as well as mental status, respiratory rate, 
oxygen saturation and temperature. This recommendation neither specifies which method 
should be used to quantify gastro-intestinal losses and urine output (e.g. collection in buckets 
or catheters), nor the threshold for applying specific interventions. The panel believed these 
specific decisions should be made by clinicians exercising their clinical judgement after 
considering, case-by-case, all context-specific benefits and risks.42,43  
 
4. We recommend (strong) that provision for serum biochemistry be available, that testing 
be conducted as deemed desirable by the attending clinicians, that results be charted, and 
the interventions in response to results be implemented according clinicians' judgment (low 
confidence). 
 
Observational study of EVD: In a cohort study of 150 EVD patients in Sierra Leone, serum 
potassium and acid-base disturbances were associated with increased risk of death:44 3/69 
(4%) survivors and 10/28 (36%) non-survivors had a potassium measurement >5.1mmol/L 
(P<0.001 after adjusting for severe acute kidney injury). Low total CO2 (38.8%, n=18), 
hyponatremia (31.8%, n=113), hypokalemia (19.6%, n=97), and hyperkalemia (13.4%, n=97) 
were common in patients with EVD; 44 all are independent predictors of mortality.35-39  
Although all are surrogate markers for risk of death – mostly from cardiac arrhythmias or 
brain oedema – reversal of electrolyte derangements may mitigate the risk. 
 
Low- versus high-income countries: See evidence summary accompanying recommendation 
2. In the United States and Europe, clinical management systematically included close 
monitoring and correction of biochemical abnormalities.23 
 
Human-to-human EBOV transmission: Blood sampling, transport and laboratory testing 
carries some risk of EBOV transmission. As mentioned in the evidence summary 
accompanying question 2, the absolute risk is small and can be mitigated by the proper IPC 
practices and equipment, including needles with safety features. Moreover, virologic testing 
for Ebola diagnosis already requires blood sampling from infected patients. Therefore, 
measurement of serum electrolytes is possibly associated with a small incremental risk of 
EBOV transmission.  
 
Conclusion: Measuring and charting serum biochemistry with clinically relevant correction of 
abnormalities may reduce mortality. This intervention may result in a small increase in the 
risk for EBOV transmission to health workers.  
 
Remark: Whenever possible, biochemistry tests should be consolidated with EBOV testing 
and blood sampled via an existing intravenous line or needles with safety features to minimise 
the risk of needlestick injury. In addition to the expected survival benefits associated with 
treatment of severe biochemical abnormalities, the intervention could reduce iatrogenic 
deaths caused by inappropriate administration of electrolytes (e.g. potassium in acute renal 
failure),44 and brain oedema associated with rapid correction of hypernatremia with 
hypotonic solutions. 
 
5. We recommend (strong) Ebola treatment unit staffing ratio of ≥1 clinician to 4 patients, 
including the following considerations: patient assessment ≥3 times per day and continuous 
(24h per day) monitoring of patients to allow prompt recognition of and reaction to acute 
changes in condition (moderate confidence). 
 
Observational data in high-income countries: A meta-analysis of 5 observational studies found 
that an increase by one nurse full-time equivalent per patient-day was associated with a 
reduced risk of death in intensive care units (odds ratio 0.91, 95% CI 0.86 to 0.96). There was 
a clear dose-response relationship.45  
 
Low- versus high-income countries: See evidence summary accompanying recommendation 
2. In the United States and Europe, patients were treated in units with a nurse:patient ratio 
of 1:1 or more and continuous monitoring.23  
 
Human-to-human Ebola virus transmission: See evidence summary accompanying 
recommendation 1. Increasing the clinician:patient ratio probably increases health worker 
time in contact with patients. However, higher clinician:patient ratios may also prevent 
fatigue, especially working in full PPE for extended periods, thereby preventing IPC mistakes. 
However, no published data has addressed this issue. 
 
Conclusion: higher clinician-to-patient ratios probably reduce mortality; the direction of 
effect, if any, on the risk of EBOV transmission is unknown.  
 
Remark: The term clinician encompasses nurses, clinical officers and physicians. In practice, 
clinicians work with a partner or team in the isolation zone in order to ensure adherence to 
appropriate IPC practices. The minimum recommended clinician:patient ratio is an average 
(e.g. could vary within ETUs based on clinical severity). The clinical contact time likely 
influences care more than staffing ratios per se. Monitoring of patients may be facilitated by 
ETU design and technology.46 Non-clinician health workers may reinforce clinical staff (e.g. to 
assist in oral rehydration solution administration). 
 
6. We suggest (conditional) facilitating communication with family and friends for patients 
admitted to the treatment unit with suspect, probable or confirmed Ebola virus disease 
(low confidence).  
 
Psychological distress: Four studies found that hospitalized patients who were isolated had 
higher depression and anxiety scores than those that were not isolated, while one study did 
not.47 Other impacts on psychological well-being included anger/hostility, fear, and 
loneliness.47 In West Africa, community distress over unknown activities in ETUs generated 
resistance, on occasions ranging from denying healthcare worker access to violent 
opposition.48  
 
Human-to-human EBOV transmission: Risk of EBOV transmission to visitors is zero under strict 
isolation. The risk is probably extremely low if contact is allowed across a sufficient distance 
or a barrier to prevent droplet spread.  
 
Conclusion: Facilitating communication of isolated patients with family and friends, including 
enabling the use of cell phones or the internet, might reduce psychological distress and can 
be achieved without increasing the risk of EBOV transmission. Closer contact situations, 
including burials,49 may be safe if appropriate IPC practices, such as use of physical barriers, 
are employed. 
 
7. We recommend (strong) analgesic therapy, including parenteral opioids, if necessary to 
reduce pain (high confidence). 
 
Pain: Analgesic medications are beneficial for acute pain in almost all scenarios. For example, 
all opioid analgesics tested in a network meta-analysis of randomized trials improved pain 
scores compared to placebo.50 A review of morphine for post-surgical analgesia found a large, 
immediate, and dose-dependent effect on pain after administration compared to placebo.51 
 
Adverse effects: Analgesic medications may be associated with adverse effects, some of them 
serious, but evidence of the magnitude of risk applicable to the clinical management of 
patients admitted to ETUs is unavailable. This recommendation assumes that the risk of 
serious adverse effects can be minimized through good clinical practice. 
 
Human-to-human EBOV transmission: See evidence summary accompanying 
recommendation 2. 
 
Conclusion: Analgesic therapy reduces pain. 
 
Remark: Assessing whether or not non-steroidal anti-inflammatory analgesics (in particular 
those that inhibit cyclooxygenase-1/ COX1) should be avoided because of anti-platelet effects 
or risks of acute kidney injury in the setting of Ebola virus disease was not possible with the 
available evidence. This recommendation is contingent upon uniform understanding of the 
objectives and techniques of palliative care, and education may be required to address any 
negative views of opioids held by health workers.52  
 
8. We recommend (strong) prompt administration of broad-spectrum antibiotics to patients 
with suspect, probable, or confirmed EVD and high severity of illness (moderate 
confidence). 
 
Mortality: Multiple time series and randomized clinical trials conducted between 1930 and 
1950 consistently show that antimicrobials reduce mortality associated with bacterial 
infections. 53,54 
 
Antibiotic-related complications: In a multicentre prospective cohort study of 4143 patients, 
the overall incidence of healthcare–associated C. difficile infection was 28.1 cases per 10 000 
patient-days.55 The odds ratio of C. difficile infection for antibiotics was 5.25 (95% CI 2.2 to 
12.8). In a retrospective cohort study of 34 298 adult inpatients in a large acute care teaching 
hospital, the overall incidence of C. difficile infection was 5.95 per 10,000 patient-days.56 Each 
10% increase in ward-level antibiotic exposure (measured in days of antibiotic therapy per 
100 patient-days) was associated with a 2.1 per 10,000 (P < .001) increased incidence in C. 
difficile. In a longitudinal cohort study of 110 656 older adults residing in nursing homes, the 
risk of allergic reactions varied from 0% in low antibiotic exposure homes to 0.1% high 
antibiotic exposure homes.57 
 
Antibiotic resistance: Antibiotic use may increase antibiotic resistance. However, the volume 
of antibiotic use associated with this recommendation in managing patients during an EVD 
outbreak likely represents a negligible increase in overall use of antibiotics and is therefore 
unlikely to have a significant impact on resistance. 
 
Human-to-human EBOV transmission: See evidence summary accompanying 
recommendation 2.  
 
Conclusion: Prompt administration of antibiotics probably reduces mortality among patients 
with bacterial infections. This might result in a small increase in antibiotic-related 
complications and risk of EBOV transmission to health workers.  
  
Remark: Patients with suspect, probable, or confirmed EVD and high severity of illness may 
be ill due to EBOV infection, bacterial infection, malaria, other infectious illnesses, or some 
combination. WHO provides guidance for investigation and management of malaria.58 This 
recommendation addresses the possibility of bacterial infection as a primary or concurrent 
cause of illness where microbiology laboratory infrastructure is lacking. The rationale is that 
where ruling out bacterial infections is not possible, the consequence of not treating 
undiagnosed bacterial infections would likely lead to serious incremental morbidity and 
mortality.59 In situations where microbiologic analyses are available, consideration should be 
given to obtaining cultures (blood, urine, respiratory, etc. as relevant) before initiating 
antibiotics if this can be achieved without delaying therapy. This would plausibly reduce the 
duration of initiated broad-spectrum antibiotics, considering that bacterial co-infection may 
affect a minority of patients.60 In all cases, patients should be reassessed 48 hours after 
initiation to determine whether antibiotics are still necessary (based upon clinical condition 
and culture results, if available). In adults, clinicians can infer high severity of illness from early 
warning scores discussed for recommendation In African patients under 15 years old who are 
hospitalized for a febrile illness, the prevalence of bacteremia is high and therefore we 
recommend prompt antibiotics regardless of illness severity.61 Critically ill patients will 
generally receive intravenous antibiotics, but clinicians could choose to administer oral 
antibiotics after considering bioavailability and likelihood of absorption (i.e. no vomiting).  
 
Conclusion 
 
First-hand accounts of the care that was delivered during the 2013-2016 West African 
outbreak provided impetus for these guidelines that address interventions considered routine 
in many contexts.62  
 
Indirectness considerably limits the quality of the evidence that informed these 
recommendations. One of the reasons for this dearth of evidence is that during more than 40 
years, after 18 outbreaks and more than 30 000 reported EVD cases, clinical descriptions were 
mostly limited to the presenting signs and symptoms for a very small proportion of all cases 
(i.e. unrepresentative sample).63 Applying these recommendations may not only improve 
outcomes but enable data collection that will inform future practice.  
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